公开(公告)号：US20240293414A1

公开(公告)日：2024-09-05

申请号：US18634241

申请日：2024-04-12

Applicant: Kissei Pharmaceutical Co., Ltd.

Inventor： Ernest LOUMAYE ,  Jean-Pierre GOTTELAND

IPC: A61K31/519 ,  A61K38/09 ,  A61P15/00

CPC classification number: A61K31/519 ,  A61K38/09 ,  A61P15/00

Abstract: The invention provides methods of treating endometriosis in a patient by administration of a gonadotropin-releasing hormone (GnRH) antagonist, for instance, according to dosing regimens predicated on the patient's level of anti-Müllerian hormone (AMH) or β17-estradiol (E2).

公开(公告)号：US20240000785A1

公开(公告)日：2024-01-04

申请号：US18244773

申请日：2023-09-11

Applicant: Kissei Pharmaceutical Co., Ltd.

Inventor： Ernest LOUMAYE ,  Jean-Pierre GOTTELAND ,  Oliver POHL

IPC: A61K31/519 ,  A61P5/00 ,  A61K31/565 ,  A61K31/57

CPC classification number: A61K31/519 ,  A61K31/57 ,  A61K31/565 ,  A61P5/00

Abstract: The invention provides compositions and methods for reducing the volume of menstrual blood loss in a patient, such as a human patient, for instance, that has uterine fibroids, by administration of a gonadotropin-releasing hormone (GnRH) antagonist. Suitable GnRH antagonists useful in conjunction with the compositions and methods described herein include thieno[3,4d]pyrimidine derivatives, such as 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4d]pyrimidine-5-carboxylic acid and the choline salt thereof.